104 results about "Protein domain" patented technology

The invention relates to the technical field of pharmaceutical knowledge maps, in particular to a pharmaceutical knowledge map construction method and system based on artificial intelligence, and the method comprises the following steps: querying and collecting a molecular structure of a drug and a corresponding target protein sequence through a database, and carrying out the numerical coding of the molecular structure data of the drug, molecular fingerprints and protein structural domain features are extracted, and a drug and protein feature set is formed by combining drug chemical attributes and protein sequence features. According to the invention, through accurate analysis of the molecular structure of the drug and the target protein sequence thereof, the innovative scheme significantly enhances the understanding of the interaction of the drug and the protein, so that researchers can directly extract key features from data and monitor the dynamic change of the drug effect, thereby not only accelerating the development process of the drug, but also improving the development efficiency of the drug. By dynamically tracking the interaction between the side effect of the medicine and the pathological characteristics, the scheme provides powerful data support for personalized medical treatment.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

The invention relates to the technical field of bioinformatics, in particular to a mining method and system for synthetic biology functional elements and a storage medium. The method comprises the following steps: acquiring functional demand data of a target metabolic pathway; performing evolutionary distance analysis and function prediction on homologous genes of a plurality of species according to the function demand data, and performing protein structural domain conservative classification on preset genome sequence data to obtain candidate element cluster data with function relevance; obtaining expression system data of the host cells; and according to the candidate element cluster data and the expression system data, scoring each functional element based on codon optimization degree, protein folding stability and metabolic load prediction to obtain hierarchical element suitability data. According to the method, factors such as sequence characteristics, expression efficiency and regulation and control network interaction are considered at the same time, multi-level accurate screening is achieved, and therefore the low efficiency and limitation of a traditional screening mode are overcome.

The invention relates to a protein structural domain ontology knowledge semantic annotation method and an online analysis engine system, and provides a protein structural domain semantic annotation map for a user by integrating protein structural domain data types with different definitions. According to the semantic annotation method, a mapping matrix between a structural domain / superstructural domain and an ontology term is constructed by using protein structural domain information and protein ontology annotation; performing overall and relative statistical inference based on the mapping matrix, and retaining the most relevant ontology terms; and obtaining the ontology annotation taking the structural domain as the center by following a real path rule, and for each structural domain / superstructural domain, screening an association relationship between terms according to the obtained overall and relative statistical inference results to form an ontology annotation configuration file. Compared with the prior art, the method has the advantages that a user is supported to carry out semantic annotation on the corresponding protein structural domain, meanwhile, enrichment analysis of ontology knowledge is supported, and powerful support is provided for exploration in the field of semantic annotation of the protein structural domain.

Provided herein are Avena sativa light, oxygen, voltage 2 (asLOV2) protein domains comprising one or more amino acid substitution(s) as compared to the wild type asLOV2 domain (SEQ ID NO: 1) wherein the mutant asLOV2 domain has an increased magnetic response as compared to the wild type asLOV domain.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

Disclosed are vaccine compositions, in particular, polyvalent icosahedral compositions for presentation of an mpox antigen. The disclosed compositions may contain an S particle comprising a norovirus (NoV) S domain protein and an mpox antigen, which may be linked via a linker protein domain operatively connected to the norovirus S domain protein and an mpox antigen. Fusion proteins for producing the vaccine compositions, and methods of using the disclosed vaccine composition are also provided.

The present invention relates to the field of biomedicine, and mainly relates to a vaccine design method for enhancing an antigen-presenting effect. A target antigen and a ligand such as a polypeptide or a protein domain having an E3 ubiquitin ligase binding or recruitment function are jointly coded in a same nucleic acid sequence, thereby promoting the degradation of the antigen protein by means of a proteasome approach, increasing the number and abundance of antigen peptides having antigen epitopes, and forming more peptide-MHC (p-MHC) complexes, and the complexes are presented on the surfaces of the cells, thereby enhancing subsequent immune response, and exerting an efficient tumor immunotherapy effect. The nucleic acid, the protein and the polypeptide vaccine provided have an efficient antigen-presenting effect and strong immunogenicity, and have good clinical application prospects.

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

To provide fusion proteins including two protein domains separated by a heterologous protease cleavage site.SOLUTION: The present invention provides a fusion protein including a first protein domain, which is a degradation domain, and a second protein domain, which is a transmembrane protein, where the first protein domain and the second protein domain are separated by a heterologous protease cleavage site, and the degradation domain is a carbonic anhydrase domain or an estrogen receptor (ER) domain.SELECTED DRAWING: None

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The invention relates to a marine-derived bifunctional enzyme as well as a coding gene and application thereof, and belongs to the technical field of biological enzymes. The amino acid sequence of the bifunctional enzyme PpLipO is as shown in SEQ ID NO. 2, and the nucleotide sequence of the bifunctional enzyme PpLipO is as shown in SEQ ID NO. 1. The enzyme comprises an alpha / beta hydrolase structural domain and an osmotic pressure induced protein structural domain, which are respectively PpLipOLip and PpLipOsmC. The novel marine-sourced bifunctional enzyme PpLipO is found for the first time, lipid peroxides are efficiently removed through the synergistic effect of two structural domains, on one hand, the problems that due to the fact that unsaturated fatty acid in fat-containing food is prone to oxidation, the nutritional value of the food is reduced, the sensory quality is degraded, and the edible safety risk is caused can be solved, and on the other hand, the marine-sourced bifunctional enzyme PpLipO can be used for efficiently removing the lipid peroxides; on the other hand, toxic lipid peroxides generated in skin oxidative injury can be cleared away, skin injury is relieved, and the compound can be used for preparing antioxidants.

The present application relates to pyrrolo-triazine and imidazo-triazine derivatives of general formula (I) for use in the treatment, amelioration or prevention of a group of diseases, disorders and abnormalities responsive to modulation of components of the NLRP3 inflammasome pathway or inhibition of activation thereof. Specifically, the component of the inflammasome pathway is an NOD-like receptor (NLR) family, a protein 3 (NLRP3) inflammasome containing a thermal protein domain. More specifically, the compounds have the ability to modulate the NLRP3 inflammasome pathway and are suitable for treating, ameliorating or preventing a group of diseases, disorders and abnormalities responsive to modulation, in particular reduction, of IL-1 beta and / or IL-18 levels, such as Alzheimer's disease, Parkinson's disease, non-alcoholic fatty liver disease and gout. # imgabs0 #

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for performing protein structure prediction and protein domain segmentation. In one aspect, a method comprises generating a plurality of predicted structures of a protein, wherein generating a predicted structure of the protein comprises: updating initial values of a plurality of structure parameters of the protein, comprising, at each of a plurality of update iterations: determining a gradient of a quality score for the current values of the structure parameters with respect to the current values of the structure parameters; and updating the current values of the structure parameters using the gradient.

A multi-domain fusion protein molecule is composed of an antibody single-chain molecule without an immune effect and a polypeptide receptor molecule, which specifically binds to pMHC epitope, or component part thereof or fragment thereof. These protein domains is close to the natural state, can be mixed to form a fusion protein complex molecule having a biological function, and can avoid the risk of immunogenicity caused by introducing artificial flexible peptide chains to link each domain into a single polypeptide chain molecule.

An injectable hydrogel for drug delivery is provided having a first component of repeating protein domains, and a second component cross-linked with the first component. The protein domain in the repeating protein domains is a WW protein sequence interspersed with hydrophilic protein sequences (repeats ranges from 2 to 10). The second component is an inter-bilayer crosslinked multilamellar vesicle. The vesicle is capable of containing drug cargo and eluting the drug cargo. The vesicle is derived from a first lipid and a second lipid. The surface of the vesicle has tethers, which are cross-linked with protein domains of the first component. Control over elution rate of drug cargo is accomplished through stabilization of the vesicles. Gelation occurs in a simple and rapid mixing of the two components without the necessity of additional crosslinking stimuli. Tuning of elution rate is achieved while not losing injectability. Bioresorbable components are used.

The present invention belongs to the field of biomedicine and relates to a method for designing a vaccine with enhanced antigen presentation effect, which is mainly applied to the design and preparation of structural sequences of nucleic acid, protein, and polypeptide vaccines. In the present invention, a target antigen and a ligand, such as a polypeptide or protein domain having the function of binding or recruiting E3 ubiquitin ligase, are both encoded in the same nucleic acid sequence. After the nucleic acid molecule enters the cell, fusion expression of the antigen protein and the E3 ubiquitin ligase ligand is achieved, which promotes degradation of the antigen protein via the proteasome pathway, increases the number and abundance of antigen peptides containing the antigen epitope, forms more peptide-MHC (p-MHC) complexes, and is thus presented on the cell surface, enhancing the subsequent immune response and exerting efficient tumor immunotherapy. The nucleic acid, protein, and polypeptide vaccines provided by the present invention have efficient antigen presentation effect and strong immunogenicity, and have good prospects for clinical application.

The invention provides a preparation method of a genetically modified mouse capable of mediating Tbx1 inherent disorder protein structural domain deletion. The method comprises the following steps: (a) constructing a targeting vector; (b) preparing a gene editing compound; (c) microinjection; (d) embryo transplantation and screening; (e) breeding and establishing a stable strain. Sequencing verifies that the gene modified mouse can stably express the Tbx1 mutant protein which lacks IDR and carries an N-terminal 3xFlag tag, and a homozygote mutant mouse shows remarkable developmental defects such as ventricular septal defect and craniofacial deformity; and an important genetic tool is provided for researching the action mechanism of the phase separation characteristic of the Tbx1 protein in the heart, craniofacial development and congenital heart disease (such as DiGeorge syndrome).

Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.

The present disclosure relates to compounds, complexes, compositions, kits and methods for determining interacting and / or binding sites between e.g., proteins, proteins and nucleic acids, proteins and small molecules, or intrachain protein domains. The disclosure provides rapid and direct positive identification of the contact interface region between such molecules, and can be applied to individual interacting pairs, as well as large-scale or global interactions.

The invention discloses a dengue attenuated strain and application thereof, and relates to the technical field of biomedicine. The dengue attenuated strain comprises a functional structural domain of a recoded NS2A protein, a functional structural domain of a recoded NS2B protein and / or a functional structural domain of an NS1 protein. The coding sequence of the recoded functional structure domain of the NS2A protein, the recoded functional structure domain of the NS2B protein and / or the recoded functional structure domain of the NS1 protein has reduced codon pair preference compared with the coding sequence of the corresponding parent protein structure domain. The dengue vaccine can initiate good host protective immune response, has excellent hereditary stability, and is helpful for rapid development of effective dengue vaccines.

Provided herein are compositions comprising light-and-magnetoresponsive protein domain, such as engineered light-oxygen-voltage-sensing (LOV) domains, and methods of using the same. The light-and magnetoresponsive proteins domains may be used to form compositions such as fusion proteins comprising heterologous protein components and bioluminescent protein domains with activity that is dependent on the presence of light, e.g., light emitted by a reaction catalyzed by the bioluminescent protein domain, and on the presence of a magnetic field.

Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.

Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.

A CRISPR-Cas system and applications thereof are provided, also related to a Cas protein, a fusion protein and a guide polynucleotide. The Cas protein has at least 50% sequence identity compared to the sequence set forth in any one of SEQ ID NOs: 1-184, 426-428. The fusion protein comprises the Cas protein fused to a protein domain and / or a polypeptide tag. The guide polynucleotide comprises a direct repeat sequence having at least 70% sequence identity to any one of SEQ ID NOs: 185-199, 245-247, 287-303, 369 and 370-373, and a guide sequence engineered to hybridize to a target nucleic acid. The CRISPR-Cas system comprises a Cas protein having at least 90% sequence identity compared to the sequence set forth in any one of SEQ ID NOs: 1-184, 426-428, or a nucleic acid encoding thereof, and a guide polynucleotide or a nucleic acid encoding thereof.

Provided herein are methods, compositions, kits and systems for regulation of peptide function. In particular, provided herein are methods, compositions, kits and systems comprising nucleic acid constructs and fusion proteins comprising chemically-activated protein domains (CAPs) that regulate the activity of a fused peptide in the presence of a ligand.

A thermally responsive nanosphere for binding to biofilms including a gold nanoparticle core functionalized with a polyethylene glycol; an R2ab fusion protein construct including an anchor that is a stable globular domain having a surface accessible cysteine residue, a linker, an S. epidermidis R2ab protein of SEQ ID NO. 1, and an elastin-like polypeptide. The linker may be a protein having SEQ ID NO. 7; and the anchor may be a modified third IgG binding domain from streptococcal protein G (GB3) having SEQ ID NO. 3, a ubiquitin protein having SEQ ID NO. 4, a Pin1 WW domain having SEQ ID NO. 5, and a fibronectin protein domain 3FN3 having SEQ ID NO. 6. A method for treating a biofilm containing S. epidermidis bacteria by binding a plurality of the nanospheres to the biofilm and exposing the biofilm to laser irradiation.

Aspects of the present disclosure include compositions and methods for treating a variety of diseases / disorders using an engineered host cell, where the engineered host cell comprises a chimeric adaptor (CAD) polypeptide comprising DAP10 and at least one chimeric receptor. The CAD polypeptides may comprise substituted mutations and / or additional protein domains that function in binding to associated receptors to enhance cell survival and proliferation of the host cells and enhance cell killing activity of non-host cells.